Literature DB >> 30237812

Plan reproducibility of intraoperatively custom-built linked seeds compared to loose seeds for prostate brachytherapy.

Tomoya Kaneda1,2, Toshio Ohashi1,2, Masanori Sakayori1,2, Shinya Sutani1, Shoji Yamashita2, Tetsuo Momma3, Shinichi Takahashi2, Takashi Hanada1, Naoyuki Shigematsu1.   

Abstract

PURPOSE: Few studies have compared the implant quality of linked and loose seeds for prostate brachytherapy. This study aimed to evaluate and compare plan reproducibility of intraoperatively built custom linked seeds and loose seeds for prostate brachytherapy.
MATERIAL AND METHODS: Between December 2010 and March 2014, 76 localized prostate cancer patients received Iodine-125 brachytherapy with external beam radiotherapy. Linked and loose seeds were implanted in 39 and 37 patients, respectively. The primary endpoint was the mean (± standard deviation) of the absolute change in the minimum dose received by 90% of the prostate volume between intraoperative and post-operative planning (ΔD90) to confirm plan reproducibility. Comparisons between the groups were evaluated using 2-sample t tests.
RESULTS: The ΔD90 values were 6.95 ± 11.6% and -0.41 ± 8.5% for the loose and linked seed groups, respectively (p < 0.01). The linked seed group showed decreased post-operative D90 (118.8% vs. 127.2%), V150 (51.7% vs. 66.7%), and RV100 (0.44 ml vs. 0.61 ml) compared to the loose seed group (p < 0.01), whereas lung migration tended to be reduced (0% vs. 8%).
CONCLUSIONS: The plan reproducibility of the linked seed group was better than that of the loose seed group. Moreover, the linked seed group showed less migration and lower rectal dose.

Entities:  

Keywords:  brachytherapy; dosimetry; linked seed; migration; prostate cancer

Year:  2018        PMID: 30237812      PMCID: PMC6142649          DOI: 10.5114/jcb.2018.77948

Source DB:  PubMed          Journal:  J Contemp Brachytherapy        ISSN: 2081-2841


Purpose

Permanent prostate brachytherapy is a standard treatment option for localized prostate cancer. In Japan, this treatment has been performed since 2003 and has recently gained popularity. Recent evidence has demonstrated an excellent biochemical control rate for patients treated with brachytherapy alone or in combination with external radiation [1,2,3,4,5,6]. Low-dose-rate prostate brachytherapy techniques have several variations, including loose vs. stranded seeds and preplan vs. intraoperative techniques. Until 2012, when stranded or linked seeds were first introduced, the most popular approach in Japan was the intraoperative technique using loose seeds [7,8]. However, problems with loose seeds include migration to distant sites (e.g., the lungs) [9,10,11,12] and possible deterioration of dosimetry due to this migration [10,11,13,14,15,16]. Zauls et al. [17] first reported the outline for the technique of linked seeds. With this approach, the user can create intraoperatively built custom linked seeds, using a combination of seeds, connectors, and spacers. The advantages of linked seeds include intraoperative customization, less migration, and increased stabilization due to linking, indicating the benefits of loose plus stranded seeds [18]. To date, many studies compared stranded seeds to loose seeds [9,13,14,19,20,21], but few studies have compared the implant quality of linked seeds with that of loose seeds for prostate brachytherapy [17,22,23,24,25]; however, until now, there have been no reports about the plan reproducibility of linked seeds. Generally, intraoperative dosimetry based on ultrasound would not predict biochemical outcome [26]. Post-operative D90 is an important dosimetric parameter for biochemical freedom from failure [27]. A recent report revealed that intraoperative magnetic resonance imaging/ultrasound fusion may improve prostate dosimetry [28] but post-operative computed tomography (CT)-based dosimetry remains the gold standard for the evaluation of implant quality. Therefore, the reproducibility of both intraoperative and post-operative planning is important for implant evaluation. We hypothesized that the plan reproducibility of linked seeds between intraoperative planning and post-operative planning would be good, on the assumption that linked seeds are connected to each other and do not move easily after seed placement. In the present study, to address this hypothesis, we focused on the post-operative minimum dose received by 90% of the prostate volume (D90). If the absolute change in prostate D90 (ΔD90 = post-operative D90 – intraoperative D90) is low, the plan reproducibility is considered to be high. To date, no studies on dosimetric reproducibility of linked seeds have been reported. Therefore, our study, which further investigated the usefulness of linked seeds, provides novel information on this issue. The primary endpoint of our analysis was the mean (± standard deviation) of the ΔD90 as a means to confirm plan reproducibility. The secondary endpoints were the comparisons of other dosimetric parameters as well as seed migration between linked and loose seeds for prostate brachytherapy.

Material and methods

Between December 2010 and March 2014, 76 patients with localized prostate cancer receiving Iodine-125 brachytherapy combined with external beam radiation therapy (EBRT) at the National Hospital Organization Saitama Hospital were analyzed. The following risk factors related to prostate cancer were assessed: serum levels of prostate specific antigen (PSA), Gleason score, and TNM stage. The subjects were divided into low-risk (T1-2a: PSA < 10 ng/ml and Gleason score ≤ 6), intermediate-risk (T2b: PSA 10-20 ng/ml, or Gleason score = 7), and high-risk (T2c-3: PSA > 20 ng/ml, or Gleason score ≥ 8) groups. The intermediate to high-risk group patients, and the low-risk group patients with positive core needle biopsy rates > 33% received combined therapy. This retrospective study was approved by the institutional review board. All patients underwent an ultrasonography volume study one month before implantation to determine the number of seeds needed. Loose seeds (Brachysource; CR Bard, Covington, GA, USA) were implanted in 37 patients using a Mick applicator (Mick Radio-Nuclear Instruments, Inc., Bronx, NY, USA). The mean activity per seed was 0.35 U (range, 0.29-0.46 U), and total seed activity was 19.2 U (range, 11.2-27.1 U). Linked seeds (Brachysource; CR Bard, Covington, GA, USA) were implanted in 39 patients using a Quicklink device (CR Bard, Covington, GA, USA). The mean activity per seed was 0.32 U (range, 0.27-0.38 U), and total seed activity was 18.8 U (range, 13.3-27.5 U). A medical physicist checked the intensity of Iodine-125 seed sources. Implantation was carried out using an interactive transrectal ultrasound (SSD-3500 SV; Hitachi Aloka Medical Co., Ltd.)-guided technique with a modified peripheral loading pattern by using the VariSeed 8.0 planning system (Varian Medical Systems, Inc., Palo Alto, CA, USA) [29]. The prostate, urethra, and rectal wall were contoured by a radiation oncologist. The planned target volume was defined as the entire prostate. Urethra was visualized on ultrasound images using a catheter. The width of the urethral catheter was 18 F in diameter. The prescribed dose to the planned target volume was 110 Gy for intraoperative planning. Supplemental EBRT was started one month after implantation. All patients received a median dose of 45 Gy (range, 30.6-50.4 Gy) at 1.8 Gy per fraction, using 10-MV photons delivered by a three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) with a linear accelerator (ONCOR Impression Plus; Siemens Medical Solutions, Erlangen, Germany). The prescribed EBRT dose varied according to the dosimetric findings at the time of the post-implant dosimetry. Computed tomography of the prostate was obtained one month post-operatively in the supine position, with 20 slice detector arrays (SOMATOM Sensation Open; Siemens Medical Solutions, Erlangen, Germany). Axial computed tomography images of the pelvic area were taken at a 3-mm thickness and 3-mm intervals. The post-implant planning for dosimetric assumption in clinical dosimetry was done using the VariSeed 8.0 planning system (Varian Medical Systems, Inc., Palo Alto, CA, USA). The entire prostate, excluding the seminal vesicles, was contoured from the base to the apex. As urinary catheters were not used for the post-implant dosimetry, it was not possible to identify the urethral position. We modified the post-implant urethral position with the help of their intraoperative ultrasound findings. The rectum was contoured as a solid structure defined by the outer wall on all slices showing seeds, without attempting to differentiate the inner wall or the contents. A frontal chest plain radiograph was obtained two weeks post-operatively to check for seed migration to the lungs. The calculated dosimetric parameters included the percent volume of the post-implant prostate receiving 100% and 150% of the prescribed dose (V100 and V150, respectively), and the D90. The ΔD90 was also evaluated. To analyze the entire cohort (n = 76), the delivered doses were converted to percentages of the prescribed dose. In addition, the rectal dose was expressed as the rectal volume receiving > 100% of the prescribed dose (RV100), and as the minimum dose received by the hottest 2 cc of the rectum, as recommended by the AAPM Task Group 137 [30]. The quantitative variables are described as arithmetic means and standard deviations. The normality of the sample has been confirmed statistically. The 2-sample t test was used for comparing the two groups. All tests and confidence intervals were two-sided, and a value of p ≤ 0.05 was considered to indicate statistical significance. Analyses were carried out using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA).

Results

The clinical characteristics of the 76 patients are shown in Table 1. Table 2 shows the dosimetric results of the intraoperative plan. The same predetermined dosimetric parameters for prostate (110 Gy) were used in both groups, and no dose escalation for the prostate was intended for the linked seed group. Significant differences in the V150 and seed activity were seen between the groups. Table 3 shows the dosimetric results of the computed tomography analysis from one month post-operatively. The D90, V150, RV100, and ΔD90 in the linked seed group were significantly lower compared with those in the loose seed group. Figure 1 presents a histogram of the ΔD90 values in the loose and linked seed groups. The ΔD90 in the linked seed group showed a lower mean value and narrower distribution (–0.41 ± 8.5%) than the loose seed group (6.95 ± 11.6%) (p < 0.01). Migration to the lungs was not seen in any patients in the linked seed group (0%), as compared to 3 patients (1-4 seeds per patient) in the loose seed group (8%; p = 0.070).
Table 1

Clinical characteristics

FactorLoose seed groupLinked seed groupp
n3739
Age (years)
 Median (range)73 (62-79)71 (52-79)0.090
Risk category0.27
 Low6 (16%)3 (8%)
 Intermediate26 (70%)26 (67%)
 High5 (14%)10 (26%)
Hormonal therapy11 (30%)19 (49%)0.090

Unless otherwise specified, the values are given as numbers

Table 2

Intraoperative parameters

FactorLoose seed groupLinked seed groupp
Prostate volume (ml)21.2 (5.8)21.2 (7.3)0.95
Implanted seed number55.3 (8.6)59.3 (9.4)0.060
Seed activity (U)0.35 (0.032)0.32 (0.026)< 0.001
Total seed activity (U)19.2 (3.7)18.8 (4.0)0.67
D90 (%)120.3 (5.1)119.2 (5.5)0.40
V100 (%)98.4 (1.4)98.8 (1.1)0.14
V150 (%)47.7 (6.4)43.0 (7.5)< 0.01

Values are given as the mean (± standard deviation).

D90 – the minimum dose received by 90% of the prostate volume; V100 – the percent volume of the prostate receiving 100% of the prescribed dose; V150 – the percent volume of the prostate receiving 150% of the prescribed dose

Table 3

Post-operative parameters

FactorLoose seed groupLinked seed groupp
Prostate volume (ml)22.1 (5.9)23.5 (7.4)0.37
D90 (%)127.2 (11.4)118.8 (9.2)< 0.01
V100 (%)98.7 (1.4)98.0 (1.9)0.06
V150 (%)66.7 (13.2)51.7 (11.4)< 0.001
ΔD90 (%)6.95 (11.6)–0.41 (8.5)< 0.01
RV100 (ml)0.61 (0.35)0.44 (0.27)0.03
RD2cc (%)68.1 (12.3)64.6 (10.4)0.18

Values are given as the mean (± standard deviation).

D90 – the minimum dose received by 90% of the prostate volume; V100 – the percent volume of the prostate receiving 100% of the prescribed dose; V150 – the percent volume of the prostate receiving 150% of the prescribed dose; ΔD90 – the postoperative D90 minus intraoperative D90; RV100 – the rectal volume receiving > 100% of the prescribed dose; RD2cc – the minimum dose received by 2 cc of the rectum

Fig. 1

Histogram of the difference in the minimum dose received by 90% of the prostate volume (ΔD90) in the loose and linked seed groups

Clinical characteristics Unless otherwise specified, the values are given as numbers Intraoperative parameters Values are given as the mean (± standard deviation). D90 – the minimum dose received by 90% of the prostate volume; V100 – the percent volume of the prostate receiving 100% of the prescribed dose; V150 – the percent volume of the prostate receiving 150% of the prescribed dose Post-operative parameters Values are given as the mean (± standard deviation). D90 – the minimum dose received by 90% of the prostate volume; V100 – the percent volume of the prostate receiving 100% of the prescribed dose; V150 – the percent volume of the prostate receiving 150% of the prescribed dose; ΔD90 – the postoperative D90 minus intraoperative D90; RV100 – the rectal volume receiving > 100% of the prescribed dose; RD2cc – the minimum dose received by 2 cc of the rectum Histogram of the difference in the minimum dose received by 90% of the prostate volume (ΔD90) in the loose and linked seed groups

Discussion

Our study revealed the dosimetric advantages, including less seed migration, of linked seeds compared to loose seeds. The mean of the ΔD90 significantly decreased towards zero and the standard deviation of the ΔD90 was narrow in the linked seed group (–0.41 ± 8.5%) compared with that in the loose seed group (6.95 ± 11.6%), which showed almost identical intraoperative and post-operative D90 values. Since linked seeds are connected to each other, the seeds do not move easily in the prostate after implantation. Therefore, the dose distribution of the intraoperative D90 is stable up to post-operative planning. That is, intraoperative planning can be reproduced in the post-operative planning. In previous reports [17,24], the ΔD90 showed no statistically significant difference between linked and loose seeds, unlike in our study. In our study, the prostate D90 of the intraoperative plan was almost the same as that of the post-operative plan in the linked seed group. Hence, we can achieve a reliable plan in the intraoperative phase. Our study is distinct from previous studies because we focus on dosimetric reproducibility of linked seeds using ΔD90 as an indicator. Therefore, it newly shows that intraoperative custom-built linked seeds are valuable in prostate brachytherapy. In the present study, the post-operative prostate D90, V150, and RV100 decreased in the linked seed group compared with that in the loose seed group. However, although the post-operative D90 decreased in the linked seed group compared to the loose seed group, the prescription dose was maintained (D90 > 100%). Thus, as the irradiation dose of the prostate is maintained, this difference may have little clinical impact. Further, reduction of the post-operative V150 leads to a reduction over the high-dose region of the prostate. As the rectal dose also shows downward trends, a reduction of adverse events can be expected as a result. Placing linked seeds on or adjacent to the prostate capsule can cover a dose from the extracapsular area. Since linked seeds are more spaced apart, the seed-to-seed distance is greater in the prostate compared with loose seeds; therefore, the high-dose region (V150) in the prostate may be reduced. Additionally, as linked seeds can be customized intraoperatively compared with suture-embedded seeds, the high-dose regions of the rectum may also be reduced. Table 4 shows the previous studies comparing the dose parameters between linked and loose seeds. Regarding the D90 and the rectal dose for the linked seed group, five previous reports showed no significant differences, while one report showed significantly lower doses in the linked seed group.
Table 4

Literature survey of dosimetric comparisons between linked and loose seeds

Study [ref]n (linked/loose)*ParameterLinked seedsLoose seedsp
Zauls et al. [17]91 (48/43)D90165.1%164.5%NS
ΔD90–8.3%–5.5%NS
% of RV100 > 1.3 cc27.6%16.7%NS
Jarusevicius et al. [22]230 (124/106)D90177.9 Gy184.7 Gy0.002
V10094.9%95.5%NS
V15053.2%65.3%< 0.001
RV1000.3 ml0.6 ml< 0.001
Ishiyama et al. [31]140 (74/66)D90174.4 Gy170.7 GyNS
V10096.60%95.70%NS
V15060.40%62.10%NS
RV1000.47 ml0.51 mlNS
Ishiyama et al. [24]630 (314/316)D90118.1%119.3%NS
ΔD90–3.82%–3.14%NS
V10095.5%95.5%NS
V15060.2%67.6%< 0.001
Katayama et al. [23]64 (32/32)D90180.7 Gy178.1 GyNS
V10098.2%97.0%NS
RV1000.97 ml1.00 mlNS
Inada et al. [25]74 (37/37)D90119.8%115.5%NS
V10096.9%95.2%0.02
V15057.1%64.5%0.005
RD2cc61.0%64.1%NS
Present study76 (39/37)D90118.8%127.2%< 0.01
ΔD90–0.41%6.95%< 0.01
V10098.0%98.7%0.061
V15051.7%66.7%< 0.001
RV1000.44 ml0.61 ml0.030

Values are presented as the means based on the one-month computed tomography analyses. Bold figures represent significantly higher values.

The number of patients in linked/loose seed group was indicated in parentheses.

NS – not significant, D90 – the minimum dose received by 90% of the prostate volume, V100 – the percent volume of the prostate receiving 100% of the prescribed dose, V150 – the percent volume of the prostate receiving 150% of the prescribed dose, ΔD90 – the post-operative D90 minus intraoperative D90, RV100 – the rectal volume receiving > 100% of the prescribed dose, RD2cc – the minimum dose received by 2 cc of the rectum

Literature survey of dosimetric comparisons between linked and loose seeds Values are presented as the means based on the one-month computed tomography analyses. Bold figures represent significantly higher values. The number of patients in linked/loose seed group was indicated in parentheses. NS – not significant, D90 – the minimum dose received by 90% of the prostate volume, V100 – the percent volume of the prostate receiving 100% of the prescribed dose, V150 – the percent volume of the prostate receiving 150% of the prescribed dose, ΔD90 – the post-operative D90 minus intraoperative D90, RV100 – the rectal volume receiving > 100% of the prescribed dose, RD2cc – the minimum dose received by 2 cc of the rectum Lastly, our study showed no significant difference in migration between the two groups, although a declining trend was noted in the linked seed group. We hypothesize that this finding is due to the fact that it may be difficult for the seeds to migrate out of the prostate because each linked seed is connected. Accordingly, previous studies have also shown significant reductions in the seed migration rate. Tapen et al. reported lower lung migration for stranded seeds compared to loose seeds (0.7% vs. 11%, p = 0.002) [12], and Ishiyama et al. reported lower migration in linked compared to loose seeds (0% vs. 52%, p < 0.001), and lower lung migration (0% vs. 30%) [31]. However, the impact on the dose distribution by migration is debatable. Wang et al. [32] reported that the prostate post-implant V100, D90, and rectal wall RV100 for patients without seed loss were 94.6%, 113.9%, and 0.98 cm3, respectively, as compared to 95.0%, 114.8%, and 0.95 cm3 for the group with seed loss; there were no correlations between seed loss due to migration and post-plan dosimetry. Miyazawa et al. reported that the D90 was 150.0 ± 19.6 Gy in patients without seed migration and 149.5 ± 19.4 Gy in patients with seed migration, and also found no significant difference in the post-planning dose delivered to the prostate between patients that did and did not display seed migration [33]. Of note, there are several reports on adverse events due to seed migration. Several studies have reported radiation pneumonitis, acute myocardial infarction, and secondary carcinoma due to migration [34,35,36]. Reducing migration using linked seeds may decrease these concerns. Our study has some limitations. Most importantly, this study was a retrospective analysis, and further prospective studies are needed to confirm our findings. As urinary catheters were not used for the post-implant dosimetry, there were uncertainties of urethral delineation and dosimetry. Therefore, we did not evaluate the urethral dose for post-operative planning. However, because all patients were treated by the same radiation oncologist and urologist, inter-observer variability in dosimetry should be limited in our study.

Conclusions

Linked seeds showed reduced differences in terms of the prostate D90 between intraoperative and post-operative planning compared to loose seeds. Thus, the post-operative plan was reproduced intraoperatively. In addition, the high-dose region in the prostate, and the rectal dose was decreased using linked seeds, as was the lung migration.
  36 in total

1.  Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors.

Authors:  Donald B Fuller; James A Koziol; Anne C Feng
Journal:  Brachytherapy       Date:  2004       Impact factor: 2.362

Review 2.  4D Brachytherapy, a novel real-time prostate brachytherapy technique using stranded and loose seeds.

Authors:  Stephen E M Langley; Robert W Laing
Journal:  BJU Int       Date:  2012-02       Impact factor: 5.588

3.  Comparison of intraoperatively built custom linked seeds versus loose seed gun applicator technique using real-time intraoperative planning for permanent prostate brachytherapy.

Authors:  A Jason Zauls; Michael S Ashenafi; Georgiana Onicescu; Harry S Clarke; David T Marshall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

4.  Comparison of intraoperative ultrasound with postimplant computed tomography--dosimetric values at Day 1 and Day 30 after prostate brachytherapy.

Authors:  Toshio Ohashi; Atsunori Yorozu; Kazuhito Toya; Shiro Saito; Tetsuo Momma; Hirohiko Nagata; Michio Kosugi; Naoyuki Shigematsu; Atsushi Kubo
Journal:  Brachytherapy       Date:  2007-10-23       Impact factor: 2.362

5.  Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.

Authors:  Nelson N Stone; Louis Potters; Brian J Davis; Jay P Ciezki; Michael J Zelefsky; Mack Roach; Paul A Fearn; Michael W Kattan; Richard G Stock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-06       Impact factor: 7.038

6.  AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137.

Authors:  Ravinder Nath; William S Bice; Wayne M Butler; Zhe Chen; Ali S Meigooni; Vrinda Narayana; Mark J Rivard; Yan Yu
Journal:  Med Phys       Date:  2009-11       Impact factor: 4.071

7.  Radiation pneumonitis caused by a migrated brachytherapy seed lodged in the lung.

Authors:  Noriyoshi Miura; Yoshito Kusuhara; Kousaku Numata; Akitomi Shirato; Katsuyoshi Hashine; Yoshiteru Sumiyoshi; Masaaki Kataoka; Shinsuke Takechi
Journal:  Jpn J Clin Oncol       Date:  2008-08-02       Impact factor: 3.019

8.  Loose seeds vs. stranded seeds: a comparison of critical organ dosimetry and acute toxicity in (125)I permanent implant for low-risk prostate cancer.

Authors:  Elantholi P Saibishkumar; Jette Borg; Ivan Yeung; Cheryl Cummins-Holder; Angela Landon; Juanita M Crook
Journal:  Brachytherapy       Date:  2008-03-24       Impact factor: 2.362

9.  Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy.

Authors:  Hiromichi Ishiyama; Takefumi Satoh; Atsunori Yorozu; Shiro Saito; Masaaki Kataoka; Katsuyoshi Hashine; Ryuji Nakamura; Susumu Tanji; Koji Masui; Koji Okihara; Toshio Ohashi; Tetsuo Momma; Manabu Aoki; Kenta Miki; Masako Kato; Masashi Morita; Norihisa Katayama; Yasutomo Nasu; Takashi Kawanaka; Tomoharu Fukumori; Fumitaka Ito; Ryoichi Shiroki; Yuji Baba; Akito Inadome; Yasuo Yoshioka; Hitoshi Takayama; Kazushige Hayakawa
Journal:  J Radiat Res       Date:  2015-10-22       Impact factor: 2.724

10.  Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts.

Authors:  Gregory S Merrick; Wayne M Butler; Robert W Galbreath; Ryan Fiano; Edward Adamovich
Journal:  J Contemp Brachytherapy       Date:  2015-12-30
View more
  2 in total

1.  Comparison of post-implant dosimetrics between intraoperatively built custom-linked seeds and loose seeds by sector analysis at 24 hours and 1 month for localized prostate cancer.

Authors:  Eiichiro Okazaki; Katsuyuki Kuratsukuri; Tomohiro Nishikawa; Tomoaki Tanaka; Mai Sakagami; Keiko Shibuya
Journal:  J Contemp Brachytherapy       Date:  2020-08-21

2.  Toxicity in patients treated with permanent prostate brachytherapy using intraoperatively built custom-linked seeds versus loose seeds.

Authors:  Luc Ollivier; Francois Lucia; Truongan Nguyen; Caroline Lucas; Vincent Bourbonne; Nicolas Boussion; Gaelle Goasduff; Georges Fournier; Olivier Pradier; Gurvan Dissaux; Antoine Valeri; Ulrike Schick
Journal:  J Contemp Brachytherapy       Date:  2020-12-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.